Synthetic antigen for the detection of AIDS-related disease
AssigneeBio-Rad Laboratories, Inc.
InventorWesley Loren Cosand
Life of this patent
Estimating the term…
Abstract
Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides in screening blood products.
Claims27
A method for determining the presence of antibodies to LAV/HTLV-III in a test sample suspected of containing said antibodies, said method comprising:
- combining the test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III having from eleven amino acids to about thirty-five amino acids, wherein the amino acid sequence of said peptide is a contiguous LAV/HTLV-III sequence and includes at least eleven amino acids from the following sequence:
- Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys and peptide analogues thereof having a sequence of a LAV/HTLV-III strain and having immunoreactivity to antibodies to LAV/HTLV-III;
- incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III;
- and
- determining the formation of immune complex and thereby detecting the presence or absence of said antibodies.
A method for determining the presence of antibodies to LAV/HTLV-III in a subject, said method comprising:
- combining a test sample from the subject with a peptide immunoreactive with antibodies to LAV/HTLV-III having from eleven amino acids to about thirty-five amino acids, wherein the amino acid sequence of said peptide is a contiguous LAV/HTLV-III sequence and includes at least eleven amino acids from the following sequence:
- Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys;
- incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III;
- and
- determining the formation of immune complex and therefrom determining the presence of antibodies to LAV/HTLV-III in the subject.
A test kit for determining the presence of antibodies to LAV/HTLV-III in a test sample, comprising a solid support to which is adsorbed a peptide immunoreactive with antibodies to LAV/HTLV-III having from eleven amino acids to about thirty-five amino acids, wherein the amino acid sequence of said peptide is a contiguous LAV/HTLV-III sequence and includes at least eleven amino acids from the following sequence:
- Gly-Ile-Trp-Gly-Cys-Ser-Gly-Lys-Leu-Ile-Cys
- and peptide analogues thereof having a sequence of a LAV/HTLV-III strain and immunoreactive to antibodies to LAV/HTLV-III, or conjugates of the peptides and analogues.
A method for determining the presence of antibodies to LAV/HTLV-III said method comprising:
- combining a test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III wherein the sequence of said peptide is:
- RILAVERYLKNQQLLGIWGCSGKLIC;
- incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III;
- and
- determining the formation of immune complex.
A method for determining the presence of antibodies to LAV/HTLV-III said method comprising:
- combining a test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III wherein the sequence of said peptide is:
- IKQLQARILAVERYLKNQQ;
- incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III;
- and
- determining the formation of immune complex.
A method for determining the presence of antibodies to LAV/HTLV-III said method comprising:
- combining a test sample with a peptide immunoreactive with antibodies to LAV/HTLV-III wherein the sequence of said peptide is:
- KNQQLLGIWGCSGKLIC;
- incubating for a sufficient time for immune complex formation to occur between said peptide and said antibodies to LAV/HTLV-III;
- and
- determining the formation of immune complex.
Dependencies are inferred from the claim text.